The United States Department of Justice announced that AmerisourceBergen Corporation, along with four of its subsidiaries, has agreed to a $625 million payment. This settlement resolves allegations concerning the company's handling of specific injectable medications used in cancer treatment.
The entities involved in the agreement include AmerisourceBergen Specialty Group, AmerisourceBergen Drug Corporation, Oncology Supply Company, and Medical Initiatives Inc. The Department of Justice identified these companies collectively as part of the resolution process.
According to the announcement, the allegations stem from the operation of a facility that repackaged oncology-supportive injectable drugs into pre-filled syringes. The government stated that these syringes were then distributed to physicians who were treating patients with cancer. The drugs named in the case include Procrit, Aloxi, Kytril, granisetron, Anzemet, and Neupogen.
AmerisourceBergen is described in the release as one of the largest wholesale drug companies in the United States. The company holds the number 11 position on the Fortune 500 list. The settlement amount of $625 million is the total figure agreed upon to resolve the specific allegations outlined by the Department of Justice.
The release does not provide further details regarding the specific timeline of the alleged activities or the internal processes that led to the repackaging practices. The announcement focuses on the financial resolution and the identification of the specific pharmaceutical products involved in the dispute.
